GHK-Cu (Copper Peptide): Topical vs Injectable, Evidence, Dosage & Safety

Key takeaways

• GHK-Cu is a three-amino-acid fragment of your own proteins (glycine, histidine, lysine) carrying a copper ion. In creams and serums it has about thirty years of small human studies behind it. As an injection it has none.
• The topical evidence is real but thin: a handful of 12-week cosmetic studies in 40 to 70 women, mostly conference abstracts reported by the peptide's inventor; one positive 1994 trial in diabetic foot ulcers; one negative trial in venous ulcers; one negative post-laser trial; and one 18-person eyebrow study in 2026.
• No published human study has tested injected GHK-Cu on its own for skin, hair, healing, inflammation or longevity, and no human safety, dosing or pharmacokinetic data exist. Two uncontrolled hair-loss series did put copper peptide into human scalp skin, but only as one ingredient of a mixture: intradermal injections of a growth-factor formulation containing copper tripeptide-1 and thymosin beta-4 (Kapoor 2018), and copper peptides tattooed in together with minoxidil and dutasteride in seven men (Kuceki 2025); neither can attribute any effect to the copper peptide. The milligram doses in online dosing charts are extrapolated from rodents and from seller convention.
• Injected copper bypasses the gut, which is where the body limits copper uptake. A 50 mg vial of GHK-Cu holds roughly 8 mg of elemental copper. What repeated injections do to the liver has not been studied.
• Topical GHK-Cu is legal as a cosmetic when sold without drug claims, and since May 2026 a 503A pharmacy may again compound it on prescription under FDA's interim Category 1 policy. Injectable GHK-Cu is not an approved drug, cannot be compounded by any US pharmacy as of October 2026, and came off FDA's Category 2 list in April 2026 only to wait for an advisory committee review due by February 2027. Every 'GHK-Cu injection' sold online is a research vial.

GHK-Cu at a glance

Also called

copper peptide, copper tripeptide-1, glycyl-L-histidyl-L-lysine copper, GHK-copper, Cu-GHK, blue copper peptide

Class

Naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper(II) ion; a signal peptide released during tissue damage

Route

Topical creams and serums (cosmetic); injectable vials sold online as research chemicals, with no legal source for human use

FDA status

Not an approved drug. Topical GHK-Cu is sold as a cosmetic ingredient (copper tripeptide-1) and is legal without drug claims. Injectable GHK-Cu was placed on FDA's Category 2 list in September 2023, removed on April 15, 2026 after its nomination was withdrawn, and is scheduled for advisory committee review before the end of February 2027; it still cannot be compounded by any US pharmacy.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Topical: compounded on prescription under FDA's interim Category 1 policy (since May 2026), or sold as a cosmetic; injectable: no legal source

Best-studied use

Topical: photoaged facial skin (small cosmetic studies), diabetic foot ulcers (one 1994 trial), venous ulcers (negative), post-laser skin (negative), eyebrow hair (one 18-person study in 2026). Injectable: no human studies of any kind.

Typical monthly cost (telehealth, 2026)

Topical serums from drugstore to prestige prices; compounded topical preparations priced like other compounded creams; no legitimate injectable product exists to price

What GHK-Cu is and how it works

GHK is glycyl-L-histidyl-L-lysine, a peptide three amino acids long. It was isolated from human blood in 1973 by Loren Pickart, who reported a factor in serum that kept normal liver cells alive in culture and, in the same paper's title, stimulated growth in neoplastic liver tissue (Pickart and Thaler 1973). The sequence occurs inside larger proteins, including collagen, and the current view is that GHK is released when tissue is cut, burned or inflamed, then binds a copper ion (Cu2+) to form GHK-Cu, the active complex. Copper makes up about 16 percent of the complex by weight; the rest is peptide.

What GHK-Cu does in a dish and in animals is consistent and well described: it stimulates fibroblasts to make collagen, elastin and glycosaminoglycans, raises both matrix metalloproteinases and their inhibitors, the balance a healing wound needs, and attracts immune and endothelial cells, the cells that build new capillaries (Pickart 2015). The cleanest animal experiment is a 1993 study from Reims: GHK-Cu injected into wound chambers under the skin of rats raised collagen, DNA and glycosaminoglycan content dose-dependently, with type I and III collagen genes up, while a control tripeptide did nothing (Maquart 1993). That paper is the biological basis for everything sold under the name copper peptide.

Two other ideas run through the GHK-Cu literature. The first is that blood levels of GHK fall with age, from about 200 ng/mL at 20 to about 80 ng/mL at 60; the figure appears in Pickart's reviews without a primary citation and has not, to our knowledge, been independently measured (Pickart 2018). The second is the gene story: using the Broad Institute's Connectivity Map, a database of how cultured cells respond to compounds, GHK was found to reverse gene-expression patterns associated with certain diseases. The most credible came from Boston University, where GHK reversed an emphysema-related gene signature in lung fibroblasts from smokers with COPD and restored the cells' ability to contract collagen (Campbell 2012), a real finding in a dish; nobody has given GHK to a person with COPD and measured anything.

Who wrote the GHK-Cu literature, and why it matters

Most of what you will read about GHK-Cu traces back to one source. Loren Pickart discovered the peptide, patented uses of it, and with his company published reviews between 2008 and 2018 that collect the cosmetic studies, the animal data and the gene analyses and conclude that the molecule's actions are, in the authors' words, all health positive (Pickart 2018). They are the inventor's summary of the inventor's work, and most of the human cosmetic studies they cite were sponsored by companies selling GHK-Cu products and never published in full.

An independent assessment arrived in August 2026, when a Romanian pharmaceutics group published a structured evidence map of every GHK-Cu study they could find, graded for biological evidence and chemical quality. Their verdict: the preclinical effects are consistent, the clinical evidence is sparse and does not meet modern standards, the historical cosmetic reports are small or incompletely characterized, and GHK-Cu should be regarded as promising but unproven rather than a validated regenerative drug (Mateescu 2026). They also note that what counts as GHK-Cu changes with the formulation: how much copper is bound, how much is loose, and whether the complex survives contact with skin or blood are rarely measured.

What the evidence actually shows

GHK-Cu claims, graded by the evidence behind them (topical unless stated)

Claim	Grade	What the evidence shows	Sources
Topical GHK-Cu improves photoaged facial skin (fine lines, firmness, thickness)	C	A 12-week facial-cream study in 71 women and a 12-week eye-cream study in 41 women (against placebo and a vitamin K cream) reported fewer lines and thicker, firmer skin; both were 2002 conference abstracts that were never published in full. A 2005 book chapter describes 67 women aged 50 to 59 with similar results, and a 1998 pilot found more collagen on biopsy than vitamin C or retinoic acid creams. All are small, industry-run and reported mainly in the inventor's reviews.	Pickart 2018; Pickart 2015; Mateescu 2026
Topical GHK-Cu speeds healing of diabetic foot ulcers	B	A multicenter randomized, evaluator-blinded, placebo-controlled trial of a GHK-Cu gel applied daily after debridement reported 98.5 percent median ulcer closure versus 60.8 percent with vehicle, and fewer ulcer infections (7 versus 34 percent). It was never replicated and the product was not developed further.	Mulder 1994
Topical GHK-Cu heals venous leg ulcers	D	In 86 patients randomized to a 0.4 percent GHK-Cu cream, silver sulfadiazine cream or placebo, the copper peptide was no better than placebo; silver sulfadiazine beat both.	Bishop 1992
Topical GHK-Cu speeds recovery after laser resurfacing	D	13 patients randomized to skin care with or without GHK-Cu after CO2 laser resurfacing: no difference in redness, wrinkles or skin quality on blinded and computer assessment; patients using GHK-Cu reported higher satisfaction.	Miller 2006
Copper peptides grow hair	C	One 2026 randomized, vehicle-controlled split-face study of a 2 percent GHK-Cu serum in 18 people reported more and thicker eyebrow hairs at 12 weeks. Everything else is animal or ex vivo: a related copper peptide enlarged follicles on rats, and AHK-Cu, a cousin of GHK-Cu, elongated human hair follicles in culture. No scalp trial in pattern hair loss exists.	Mateescu 2026; Uno 1993; Pyo 2007
GHK-Cu stimulates collagen and wound matrix	C	In rat wound chambers, injected GHK-Cu raised collagen, DNA and glycosaminoglycan content dose-dependently; a control tripeptide did not. Human support is limited to small biopsy studies of topical creams. The mechanism is credible; the clinical payoff is what remains unproven.	Maquart 1993; Pickart 2015
GHK resets gene expression toward youth (anti-aging, longevity)	D	The gene claims come from database screens and cell culture. The best independent result is that GHK reversed an emphysema-related gene signature in COPD lung fibroblasts in a dish. No study has measured aging, lifespan or any organ outcome in humans.	Campbell 2012; Pickart 2018
Injected GHK-Cu improves skin, hair, healing, inflammation or longevity	D	No published human study of injected or systemic GHK-Cu on its own exists for any outcome; two uncontrolled scalp series used it only inside multi-ingredient mixtures. A 2026 sports-medicine primer and the 2026 pharmaceutics review both note the gap; so did every clinician NPR interviewed in September 2026.	Mateescu 2026; Mayfield 2026; NPR 2026
Injected GHK-Cu is safe	D	No human safety or pharmacokinetic data. Theoretical concerns are copper overload with oxidative liver injury, immune reactions to impurities and aggregates (FDA's reason for the 2023 Category 2 listing) and unknown effects on tumor blood supply. A Seattle-area clinician told NPR he has seen self-injectors with elevated liver enzymes and copper levels.	Moiz 2026; Mateescu 2026; FDA Category 2; NPR 2026

Three things stand out.

The wound data cut both ways. The diabetic-ulcer trial is the strongest human result GHK-Cu has, and it is thirty years old, unreplicated and attached to a product that disappeared (Mulder 1994). Two years earlier a similar GHK-Cu preparation had failed in venous ulcers, where a cheap antibiotic cream did better (Bishop 1992). Marketing leaves out both, one because it was never followed up, the other because it was negative.

The cosmetic data are small, old and owned. Seventy-one women for twelve weeks is a respectable cosmetic study, but it exists only as a conference abstract and the only place to read its results is the inventor's reviews. The one cosmetic trial run by surgeons with blinded assessment, after laser resurfacing, found nothing objective (Miller 2006). The honest summary is that topical GHK-Cu probably does something modest to skin texture over two to three months, about what other active cosmetic ingredients do, and nobody has run the trial that would settle it. A properly designed one is finally registered: a 60-person, vehicle-controlled split-wound study of a 0.1 percent GHK-Cu gel on punch-biopsy wounds, started in February 2026 and due to finish in 2027 (NCT07437586).

The injectable data do not exist. This is not weak evidence; it is none. PubMed searches for human studies of injected, subcutaneous or intravenous GHK-Cu return nothing, and the 2026 reviews by people with no stake in the product say the same (Mayfield 2026). Everything you have read about GHK-Cu injections is extrapolation from creams, rodents and cells.

What you are promised versus what is documented

Sales pages for copper peptides, topical or injectable, make the same list of promises: tighter skin, fewer wrinkles, faster wound healing, thicker hair, less inflammation, better sleep and mood, and reversed aging. The evidence sorts them into three bins.

• Documented in humans, topically, in small studies: modest improvement in skin thickness, firmness and fine lines after 8 to 12 weeks; faster closure of diabetic foot ulcers in one trial; more eyebrow hair in one 18-person study.
• Plausible but unproven in humans: scalp hair regrowth; faster healing of ordinary cuts, burns or post-procedure skin (the laser trial was negative); any anti-inflammatory effect at the whole-body level.
• Not supported: anything from an injection; longevity, lifespan or healthspan; mood, anxiety or cognition (rodent and gene-database work only); COPD or lung repair in people; protection against cancer or metastasis (database signals in both directions, no human data).

The last bin deserves one more sentence. GHK was discovered because it affected liver cells, including cancerous ones (Pickart and Thaler 1973), and copper is one of the signals tumors use to grow blood vessels; Pickart's reviews argue, from database screens, that GHK suppresses metastasis-related genes (Pickart 2018). Both are hypotheses, and neither has been tested in a person, which is a reason not to inject the molecule with a cancer history, not a reason to.

Topical versus injectable: the whole story

The pivot from creams to needles happened on social media, not in a laboratory. NPR's September 2026 report quoted a cosmetic dermatologist who calls the topical science solid and tells patients to hold off on injections, a University of Washington researcher who has studied the peptide for years and would not inject it himself, and a wellness-clinic clinician who sees the complications and little benefit (NPR 2026). We could not find a dissenting expert with data.

Why the 'GHK-Cu injections' sold online are research vials

There is no approved GHK-Cu drug anywhere in the world, and no US pharmacy may legally compound an injectable version: a 503A pharmacy may only use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on FDA's permitted list, and injectable GHK-Cu meets none of the three (FDA 503A). The vials labeled GHK-Cu 50 mg are therefore synthesized in bulk, usually overseas, filled by a reseller, and sold with a research-use disclaimer that FDA has said does not survive a website explaining how to dose and inject the product; the agency's August 24, 2026 warning letters to five peptide vendors cited exactly that content. Our legal tracker covers the letters and the law.

What a research vial does not come with is anything that makes a medication a medication: verified identity and content, sterility and endotoxin testing you can see, a label with a concentration and a beyond-use date, a pharmacist, and a clinician who will measure your copper and liver enzymes. The 2026 pharmaceutics review lists what an injectable copper peptide would have to characterize first: sterility, endotoxin, particles, aggregation, how much copper is loose, and what repeated doses do to the liver. None of it has been done (Mateescu 2026).

Dosage: what was studied versus what circulates online

Topical GHK-Cu as studied

Retail serums in October 2026 typically list copper tripeptide-1 at 0.5 to 3 percent, with 1 percent common. No published study compares concentrations, so a higher number on the label is a marketing decision, not a dose-response finding. The schedule with data behind it is once or twice daily for 8 to 12 weeks, after a patch test.

Injectable GHK-Cu as circulated (claims, not studied doses)

The copper arithmetic

The part of these charts that can be checked is the copper. GHK-Cu has a molar mass of about 402 g/mol, of which copper is about 63.5, so copper is roughly 16 percent of the weight: a 2 mg injection delivers about 0.3 mg of elemental copper, and a 50 mg vial holds about 8 mg. For scale, human balance studies find net copper loss at dietary intakes below about 0.8 mg a day and net gain above about 2.4 mg a day, and the body keeps copper in range mainly by limiting absorption in the gut and excreting the excess in bile (Bost 2016). An injection skips the first control. Free copper catalyzes hydroxyl-radical formation, and copper overload is a recognized cause of oxidative liver injury (Gaetke 2003). None of this proves that 0.3 mg a day under the skin is harmful; it shows nobody has measured whether it is, and that oral safety limits cannot be converted into limits for injection (Mateescu 2026).

Reconstitution example

Seller charts usually read like this: a 50 mg vial plus 2 mL of bacteriostatic water gives 25 mg/mL, so 1 mg is 0.04 mL, or 4 units on a U-100 insulin syringe. The arithmetic is correct, our peptide calculator will do it for any vial, and it is the only part of the chart that is; the vial's content, sterility and effect are all unverified.

Side effects and who should not use it

Topical. The documented problems are mild: stinging or redness, usually from the vehicle or from combining copper peptides with acids and high-dose vitamin C in the same application, and allergic contact dermatitis in people sensitized to copper, a known risk of any copper-containing product (Mateescu 2026). Stop if a rash spreads beyond where you applied it. There is no evidence of systemic effects from cosmetic use.

Injected. Unknown, because unstudied. The nameable risks are generic to research-vial injections (injection-site infection, endotoxin fever, wrong dose, and immune reactions to peptide impurities and aggregates, the concern FDA cited when it put injectable GHK-Cu in Category 2 (FDA Category 2)) plus one specific to this molecule: copper. A 2026 cardiology review describes systemic copper disrupting copper homeostasis and driving oxidative stress and possible liver injury as a theoretical risk with no human data either way (Moiz 2026). The self-injectors with elevated liver enzymes and copper levels in NPR's report are the kind of signal that goes unreported when no pharmacy or clinician is in the chain (NPR 2026).

Do not use injected GHK-Cu, and talk to a clinician before using topical products, if you have:

• Wilson disease or any other disorder of copper metabolism, or chronic liver disease;
• a known copper or metal allergy;
• a current or recent cancer (copper and GHK both act on blood-vessel growth, and the human data are absent);
• pregnancy or breastfeeding (no data; topical cosmetic use is a different question from injection);
• a child's skin or scalp (no pediatric data).

GHK-Cu is not on the WADA prohibited list by name as of October 2026, but athletes should treat any research-vial injection as a doping and contamination risk.

Legal status in the United States

GHK-Cu lives in two legal worlds, and most of the confusion online comes from mixing them up.

As a cosmetic ingredient, it is legal. Cosmetics do not need FDA approval before sale; the company is responsible for safety and for the truth of its claims, and the 2022 Modernization of Cosmetics Regulation Act added facility registration, product listing and adverse-event reporting without changing that rule (FDA cosmetics law). What a cosmetic may not do is claim to treat a disease or change the body's structure or function: 'reduces the appearance of fine lines' is a cosmetic claim, 'stimulates collagen synthesis' or 'regrows hair' is a drug claim, and a product making it is an unapproved drug whatever the label says (FDA, cosmetic or drug). That is why the research literature's language does not appear on compliant packaging.

As an injectable, it is not legal to sell for human use and cannot be compounded. In September 2023 FDA placed GHK-Cu for injectable routes in Category 2 of its 503A bulk-substances evaluation, the list of nominated substances the agency found may present significant safety risks, citing immunogenicity from aggregation and peptide impurities and the absence of human data (FDA Category 2). On April 15, 2026, FDA announced that injectable GHK-Cu was one of twelve peptides coming off Category 2 because their nominations had been withdrawn; the same notice removed non-injectable GHK-Cu from Category 1, the interim list that had allowed compounding during evaluation. Both are scheduled for Pharmacy Compounding Advisory Committee review before the end of February 2027, and the compounding lawyers who follow the list were explicit that removal does not make a substance eligible for compounding (Frier Levitt 2026). The Category 1 removal, effective April 22, 2026, did not last: after a nominator clarified on May 5, 2026 that it had withdrawn only the injectable route, FDA returned non-injectable GHK-Cu to Category 1 (FDA categories 2026). As of October 2026, no US pharmacy may compound injectable GHK-Cu, while a 503A pharmacy may compound topical GHK-Cu on prescription under the interim policy until the committee review; the legal tracker will update when FDA acts.

Compounded topical preparations are permitted, for now. Some compounding pharmacies prepare GHK-Cu creams and serums, often mixed with hair-loss or acne drugs. A cosmetic preparation with no drug claims falls under the cosmetic rules; a prescription drug product needs a 503A basis for each bulk ingredient, and for topical GHK-Cu that basis is its Category 1 listing, restored in May 2026, which lets pharmacies compound it while FDA evaluates it (FDA categories 2026). If a clinician prescribes one, ask the pharmacy what its basis is for every other ingredient in the mix.

Cost and how to get it

For the topical, the market is mostly the cosmetics aisle: copper-peptide serums run from drugstore to prestige prices, and the concentration on the label has no proven relationship to the result. A compounding pharmacy can also prepare a topical GHK-Cu cream on prescription, which FDA's interim Category 1 policy has allowed again since May 2026. A clinician-guided skin program is a different proposition: a dermatologist or telehealth clinician who builds a regimen around prescription retinoids, sunscreen and the few active cosmetic ingredients with data, which can include a topical copper peptide, and who photographs your skin before and after so the result is measured rather than felt. Our cost guide covers consultation and program fees in 2026.

For the injectable there is nothing legitimate to buy, so there is nothing to price. A program that lists GHK-Cu injections next to sermorelin or glutathione is mixing a compoundable medication with a research vial.

GHK-Cu for women and older adults

Almost all the human cosmetic data come from women in their forties to sixties, the population the products are marketed to: the 12-week facial and eye-cream studies enrolled women with mild to advanced photoaging, the eyebrow study healthy adults, the ulcer trials older patients of both sexes. None measured anything in pregnancy, and the sensible position for a cosmetic with a copper ion in it is to skip it while pregnant or breastfeeding unless a clinician says otherwise. The claim that GHK falls with age and should be replaced is the inventor's and has no replacement trial behind it. See peptides for women for how copper peptides compare with the compounds that do have data.

Bottom line

Topical GHK-Cu is a reasonable cosmetic ingredient with thirty years of safe use and a few small studies suggesting modest improvement in skin firmness and fine lines, one unreplicated win in diabetic ulcers, one loss in venous ulcers, and one 18-person eyebrow study. It is legal, cheap and low-risk, and it is not a substitute for a retinoid or sunscreen.

Injectable GHK-Cu is a different product with the same name: no human studies, no safety data, no legal source, and a copper load the body was not designed to receive by needle. The doses online are guesses. FDA's advisory committee review in early 2027 may change what pharmacies can do; it will not change the evidence, which would still have to be generated. Until it is, the honest advice is the dermatologist's in NPR's report: use the cream if you like it, and hold off on the injections.

Frequently asked questions

+−What is GHK-Cu?

GHK-Cu is a fragment of your own proteins, three amino acids long (glycine, histidine, lysine), carrying a copper ion. It was found in human blood in 1973 and appears to be released when tissue is damaged, where it helps organize repair: more collagen and other matrix, controlled breakdown of damaged matrix, and recruitment of immune and blood-vessel cells. In skincare it is listed as copper tripeptide-1. The same molecule is now sold in vials for injection, for which there is no human research.

+−Is GHK-Cu safe?

On the skin, yes for most people: decades of cosmetic use and several small studies report only occasional irritation, and copper can cause contact allergy in a minority. Injected, nobody knows. There is no human study of injected GHK-Cu, no pharmacokinetic data and no safety data. The specific worries are copper overload (the gut normally limits copper uptake and injections bypass it), immune reactions to impurities, and sterility of research vials. One clinician told NPR in September 2026 that he has seen self-injectors with elevated liver enzymes and copper levels.

+−Does GHK-Cu work for hair loss?

There is no trial of GHK-Cu in men or women with pattern hair loss. The evidence is a 2026 split-face study in 18 people in which a 2 percent GHK-Cu serum increased eyebrow hair count and thickness at 12 weeks, plus older animal and test-tube work with related copper peptides. Minoxidil and finasteride have decades of controlled trials; copper peptides have twelve weeks of eyebrows. Injecting GHK-Cu for hair has no evidence at all.

+−Which is better, NAD+ or copper peptides?

They are not alternatives to each other. GHK-Cu is a topical skin ingredient with small cosmetic studies; NAD+ is a coenzyme sold as injections and infusions for energy and aging claims with its own thin evidence. Neither has a trial showing an anti-aging outcome in people. If the question is skin texture, topical GHK-Cu at least has studies in the right place; if the question is longevity, neither has earned the claim.

+−How often should you use GHK-Cu?

In the cosmetic studies, creams were applied once or twice daily for 8 to 12 weeks; the 2026 eyebrow study used a serum twice daily for 12 weeks; the registered wound trial applies a 0.1 percent gel once daily for 14 days. Those are the only schedules with any data. The daily or five-days-a-week injection schedules circulated online have never been tested in humans and are not recommendations.

+−What should you not mix copper peptides with?

Formulators usually keep copper peptides away from strong acids and high-dose vitamin C in the same step, because low pH and ascorbate can strip or redox-cycle the copper; using them at different times of day is the common workaround. Retinoids are fine in alternation. There is no documented drug interaction for topical use. For injections, the question is unanswerable because the injections themselves are unstudied.

+−What are the negative side effects of peptide injections?

For GHK-Cu specifically: unknown, because no human study exists. What research-vial injections in general carry is well described: injection-site reactions and infections, endotoxin fever and shock from contaminated vials, wrong doses from unverified content, and immune reactions to peptide impurities and aggregates, which is the reason FDA gave for flagging injectable GHK-Cu in 2023. Copper adds a theoretical risk of liver injury with repeated dosing.

+−Is injectable GHK-Cu legal?

It is not an approved drug and no US pharmacy may legally compound it as of October 2026. FDA removed it from its Category 2 safety-risk list on April 15, 2026 only because the nomination was withdrawn; that did not add it to the permitted list. Its advisory committee review is due by February 2027. Possessing a vial is not a crime; selling one for human use is selling an unapproved drug, which FDA restated in warning letters to five vendors in August 2026.

+−What results can I expect from GHK-Cu, and how fast?

From a topical product, the studies that exist report firmer, slightly thicker skin and fewer fine lines after 8 to 12 weeks of daily use, with effects comparable to other active cosmetic ingredients, and a 13-patient post-laser trial found no objective benefit. Before-and-after photos online, especially for injections, show lighting, filters and other products as much as copper. Nobody has measured what injections do.

Sources

1. StudyPickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol 1973;243:85-7. (1973)
2. ReviewPickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108. (Authors are the inventor and his company.) (2015)
3. ReviewPickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19:1987. (Authors are the inventor and his company.) (2018)
4. StudyMaquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest 1993;92:2368-76. (1993)
5. StudyMulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen 1994;2:259-69. (1994)
6. StudyBishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg 1992;16:251-7. (1992)
7. StudyMiller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006;8:252-9. (2006)
8. StudyUno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol 1993;101(1 Suppl):143S-147S. (1993)
9. StudyPyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007;30:834-9. (Tested AHK-Cu, a related copper tripeptide.) (2007)
10. StudyCampbell JD et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med 2012;4:67. (2012)
11. StudyKapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation. J Cosmet Dermatol 2018. (Uncontrolled; mixture including copper tripeptide-1 and thymosin beta-4.) (2018)
12. StudyKuceki G et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia. 2025. (Seven men; copper peptides combined with minoxidil and dutasteride.) (2025)
13. ReviewMateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics 2026;18:1077. (2026)
14. ReviewMayfield CK et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med 2026;54:223-9. (2026)
15. ReviewMoiz A, O'Keefe EL, O'Keefe JH. Dangers of injectable peptides and other unregulated 'biohacking' drugs. Mo Med 2026;123:337-43. (2026)
16. ReviewGaetke LM, Chow CK. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 2003;189:147-63. (2003)
17. ReviewBost M et al. Dietary copper and human health: current evidence and unresolved issues. J Trace Elem Med Biol 2016;35:107-15. (2016)
18. NewsStone W. The copper peptide trend has gone from creams to injections, ahead of the science. NPR, September 7, 2026 (republished by WUNC). (2026)
19. SourceClinicalTrials.gov NCT07437586. A phase 2, randomized, double-blind, vehicle-controlled, split-wound study of topical GHK-Cu gel (0.1 percent) in healthy adults; sponsor Hudson Biotech; started February 2026, recruiting. (2026)
20. RegulatoryFDA. Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list; injectable GHK-Cu listed September 2023, citing immunogenicity concerns).
21. RegulatoryFDA. Bulk drug substances used in compounding under section 503A of the FD&C Act (the 503A bulks list and interim categories).
22. NewsFrier Levitt. FDA to remove 12 popular peptides from the Category 2 'do not compound' list (injectable GHK-Cu removed from Category 2 and non-injectable GHK-Cu from Category 1; PCAC review due before the end of February 2027). April 16, 2026. (2026)
23. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)
24. RegulatoryFDA. Is it a cosmetic, a drug, or both? (Or is it soap?) How intended use and claims decide whether a skin product is regulated as a cosmetic or a drug.
25. RegulatoryFDA. Cosmetics and US law: no premarket approval for cosmetics; the Modernization of Cosmetics Regulation Act of 2022 (facility registration, product listing, adverse event reporting).